American Cyanamid Company

University of Illinois

Roche Vitamins Inc.

Guy T Carter

Joseph J Goodman

Michael Greenstein

Donald B Borders

David P Labeda

Margaret J Torrey

Raymond T Testa

William M Maiese

David R Williams

Kenneth L Rinehart

Gerhard Schlingmann

Douglas W Phillipson

Joseph D Korshalla

Fernando Pinho

Michael T Cheng

The invention provides an antibiotic designated LL-E19020 Gamma which is derived from the microorganism Streptomyces lydicus ssp. tanzanius NRRL 18036.

Antibiotic LL-E19020 gamma

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LLF28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F28249.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Agents and method of production thereof

This invention relates to antibiotic LL-D37187.alpha. derived from the microorganism Streptomyces which is useful as an antibacterial agent.

Antibiotic LL-D37187.alpha.

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F28249.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Biologically pure culture of the microorganism, streptomyces

The invention provides antibiotics designated LL-E19020 Epsilon and LL-E19020 Epsilon.sub.1 which are derived from the microorganism Streptomyces lydicus ssp. tanzanius NRRL 18036.

Antibiotics LL-E19020 Epsilon and LL-E19020 Epsilon.sub.1

This disclosure describes novel antibacterial agents designated LL-E10985.alpha., LL-E19085.beta., LL-E19085.gamma., LL-E19085.zeta. and LL-E19085.eta., having the structure: ##STR1## their production by aerobic fermentation of a new subspecies of Micromonospora citrea NRRL 18351 and mutants thereof, and the isolation and purification thereof.

Subspecies of Micromonospora citrea which produces antibiotic LL-E19085

The invention provides an improved process for the isolation and purification of antibiotics designated LL-E19020 alpha and beta which are derived from the microorganism Streptomyces lydicus ssp. tanzanius NRRL 18036. The invention is a method of recovery, concentration from crude solutions and to processes for the purification of anitbiotics designated LL-E19020 alpha and beta which are derived from the microorganism Streptomyces lydicus ssp. tanzanius NRRL 18036.

Recovery process for antibiotics LL-E19020 alpha and beta

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F2924.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Macrolide antibiotic compounds

This disclosure describes novel antibacterial agents designated LL-E10985.alpha., LL-E19085.beta., LL-E19085.gamma., LL-E19085.gamma. and LL-E19085.zeta., having the structure: ##STR1## their production by aerobic fermentation of a new subspecies of Micromonospora citrea NRRL 18351 and mutants thereof, and the isolation and purification thereof.

Antibiotic LL-E19085

Derivatives of antibiotics derived from the microorganism Streptomyces lydicus subspecies tanzanius, referred to as antibiotics LL-E19020 alpha and beta, are produced by chemical reaction. The derivatives are also active antibiotics useful in the treatment of bacterial infections.

Chemical derivatives of antibiotics LL-E19020 alpha and beta

This invention provides a method for treating chronic respiratory disease, fowl cholera and necrotic enteritis in infected birds, by orally administering thereto a pharmaceutically effective amount of antibiotic LL-E19020.alpha., antibiotic LL-E19020.beta. or a physiologically acceptable salt thereof.

Method for controlling chronic respiratory disease, fowl cholera and

Antibiotic LL-D42067.beta. derived by aerobic fermentation of the microorganism Actinomadura madurae subspecies simaoensis NRRL 15734, useful as an antibacterial and antiparasitic agent.

Antibiotic LL-D42067.beta.

Synthetically produced substantially pure biologically active compounds having the general formula ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.20 alkyl, alkenyl, aryl, aralkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl, or cycloalkenylalkyl;

Acyl and carbamimidoyl alkanediamines

This invention relates to antibiotic LL-E19020.alpha. and LL-E19020.beta. derived from the microorganism Streptomyces lydicus subspecies tanzanius NRRL 18036, which are useful as an antibacterial agent.

Growing community of inventors

Suffern, NY, United States of America

Guy T Carter